Palisade Bio, Inc. (PALI) Stock

Palisade Bio, Inc. (PALI) is a Healthcare stock trading at $2.11 (as of 2026-08-21), with a market capitalization of $367.71M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Palisade Bio, Inc. is a clinical-stage biopharmaceutical company developing oral therapies aimed at diseases linked to loss of the mucosal barrier in the gastrointestinal tract. Its lead program, LB1148, is an oral liquid formulation intended to inhibit digestive enzyme activity to help preserve gut integrity during intestinal stress such as reduced blood flow, infections, or surgery.

Understand Palisade Bio, Inc.: how it makes money

Palisade Bio develops and commercializes oral therapies, with its lead candidate LB1148 being an oral liquid digestive enzyme inhibitor intended to help preserve gut integrity during intestinal stress.

As a clinical-stage biopharmaceutical company, Palisade’s route to profit depends on whether its lead oral therapy candidate, LB1148, successfully progresses into commercialized treatments built around preserving gut integrity during intestinal stress.

Business quality (Unprofitable): Unprofitable, operating margin -2340% (period ended 2026-06-30) indicates the business has not reached profitable operations yet.

Bull case

  • Defined gut-integrity hypothesis: LB1148 is an oral liquid formulation intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress from reduced blood flow, infections, or surgery. This creates a focused, testable biological story for the clinical development effort.

Bear case

  • Operating losses remain deep: Operating margin -2340% for the period ended 2026-06-30 signals substantial operating losses. For investors, this raises the risk that the company will need continued external resources before profitability is reached.
  • Clinical-stage execution uncertainty: As a clinical-stage biopharmaceutical company, Palisade depends on development outcomes for LB1148 becoming a commercial oral therapy. If digestive enzyme inhibition does not translate into preserved gut integrity as intended, the program could fail to progress.
Valuation — source: SEC EDGAR (first-party)
Price$2.11
Market Cap$367.71M
Price / Book3.02
Price / Sales735.42
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$0.00
Revenue Growth (YoY)-100.0%
EPS Growth (YoY)466.1%
FCF Growth (YoY)9.5%
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderJupiter Topco LLC ($22.39M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOJ. D. Finley
Employees8
CountryUS
IPO Date2007-03-30

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Compass Therapeutics, Inc. (CMPX)
  • Voyager Acquisition Corp. (VACH)
  • Lexeo Therapeutics, Inc. Common Stock (LXEO)
  • Fennec Pharmaceuticals Inc. (FENC)
  • X4 Pharmaceuticals, Inc. (XFOR)
  • Century Therapeutics, Inc. (IPSC)
  • Sutro Biopharma, Inc. (STRO)
  • Inhibikase Therapeutics, Inc. (IKT)
PALI earnings history · PALI institutional & insider holders · PALI KPIs & operating metrics · PALI financials · PALI investor presentations & press releases · PALI SEC filings · PALI peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.